Biopharmaceutical company Cannsun Medhel Group has nominated Donaghue Woodman to its board of directors.
Woodman will also head up the South African company’s women’s health division and oversee research and development of its adaptogens, which include CBD, psilocybin, and other botanicals.
“The appointment of Donaghue brings a wealth of experience in the health sector and market access fields and joins the Board at a pivotal time as we prepare to ramp up operations on three continents,” Cannsun CEO David Parry stated. “Her insights and skillset will be valuable resources as we develop and implement evidence-based medicine and women specific consumer based health products.”
Woodman, an alum of Management College of Southern Africa, will become Cannsun’s first female African-based director.
Joining Woodman is fellow South African Rorisang Ntai, who was also nominated to Cannsun’s board.
“This is important to us as we see Africa as an underrepresented market with massive potential and having successful business entrepreneurs join our board with expedite our growth,” Parry added.
Woodman and Ntai are both expected to help increase the company’s footprint.
Woodman previously worked at the South African Herbal Medicine and Science Institute, Abbot Laboratories and Adcock Ingram.
Ntai is a former Citadel Investment analyst.
Cannsun also has a European office in Greece.
Courtesy photo
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Credit: Source link
